Loading…

MicroRNA-363-3p promote the development of acute myeloid leukemia with RUNX1 mutation by targeting SPRYD4 and FNDC3B

Runt-related transcription factor 1 (RUNX1) is one of the most frequently mutated genes in most of hematological malignancies, especially in acute myeloid leukemia. In the present study, we aimed to identify the key genes and microRNAs based on acute myeloid leukemia with RUNX1 mutation. The newly f...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2021-05, Vol.100 (18), p.e25807-e25807
Main Authors: Chen, Yimin, Chen, Shuyi, Lu, Jielun, Yuan, Danyun, He, Lang, Qin, Pengfei, Tan, Huo, Xu, Lihua
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c4501-46aeeabdf432c1dd8c7eb8d29109869b34cb21808708dec5bda48c5eb137690a3
cites cdi_FETCH-LOGICAL-c4501-46aeeabdf432c1dd8c7eb8d29109869b34cb21808708dec5bda48c5eb137690a3
container_end_page e25807
container_issue 18
container_start_page e25807
container_title Medicine (Baltimore)
container_volume 100
creator Chen, Yimin
Chen, Shuyi
Lu, Jielun
Yuan, Danyun
He, Lang
Qin, Pengfei
Tan, Huo
Xu, Lihua
description Runt-related transcription factor 1 (RUNX1) is one of the most frequently mutated genes in most of hematological malignancies, especially in acute myeloid leukemia. In the present study, we aimed to identify the key genes and microRNAs based on acute myeloid leukemia with RUNX1 mutation. The newly finding targeted genes and microRNA associated with RUNX1 may benefit to the clinical treatment in acute myeloid leukemia. The gene and miRNA expression data sets relating to RUNX1 mutation and wild-type adult acute myeloid leukemia (AML) patients were downloaded from The Cancer Genome Atlas database. Differentially expressed miRNAs and differentially expressed genes (DEGs) were identified by edgeR of R platform. Gene ontology and the Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed by Metascape and Gene set enrichment analysis. The protein-protein interaction network and miRNA-mRNA regulatory network were performed by Search Tool for the Retrieval of Interacting Genes database and Cytoscape software. A total of 27 differentially expressed miRNAs (25 upregulated and 2 downregulated) and 561 DEGs (429 upregulated and 132 downregulated) were identified. Five miRNAs (miR-151b, miR-151a-5p, let-7a-2-3p, miR-363-3p, miR-20b-5p) had prognostic significance in AML. The gene ontology analysis showed that upregulated DEGs suggested significant enrichment in MHC class II protein complex, extracellular structure organization, blood vessel development, cell morphogenesis involved in differentiation, embryonic morphogenesis, regulation of cell adhesion, and so on. Similarly, the downregulated DEGs were mainly enriched in secretory granule lumen, extracellular structure organization. In the gene set enrichment analysis of Kyoto Encyclopedia of Genes and Genomes pathways, the RUNX1 mutation was associated with adherent junction, WNT signaling pathway, JAK-STAT signaling pathway, pathways in cancer, cell adhesion molecules CAMs, MAPK signaling pathway. Eleven genes (PPBP, APP, CCR5, HLA-DRB1, GNAI1, APLNR, P2RY14, C3AR1, HTR1F, CXCL12, GNG11) were simultaneously identified by hub gene analysis and module analysis. MicroRNA-363-3p may promote the development of RUNX1 mutation AML, targeting SPRYD4 and FNDC3B. In addition, the RUNX1 mutation rates in patient were obviously correlated with age, white blood cell, FAB type, risk(cyto), and risk(molecular) (P 
doi_str_mv 10.1097/MD.0000000000025807
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8104143</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>33950983</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4501-46aeeabdf432c1dd8c7eb8d29109869b34cb21808708dec5bda48c5eb137690a3</originalsourceid><addsrcrecordid>eNpdUdFu1DAQtBCIXgtfgIT8Ay52bMfOC1K5awGpd6CDSvBkOfHeJTSJI8fp6f6-bq-0lH1ZaWZnVrOL0DtGTxkt1Ifl4pQ-VSY1VS_QjEmeE1nk4iWa3aFEFUocoeNx_EMp4yoTr9ER54WkheYzFJdNFfx6dUZ4zgkf8BB85yPgWAN2cAOtHzroI_YbbKspEd0-YY3DLUzX0DUW75pY4_XV6hfD3RRtbHyPyz2ONmwhNv0W__i-_r0Q2PYOX6wWc_7pDXq1se0Ibx_6Cbq6OP85_0Iuv33-Oj-7JJWQlBGRWwBbuo3gWcWc05WCUrusSPF1XpRcVGXGNNWKageVLJ0VupJQpph5QS0_QR8PvsNUduCqlCPY1gyh6WzYG28b85zpm9ps_Y3RjAomeDLgB4N0o3EMsHnUMmrunmCWC_P_E5Lq_b9rHzV_r54GxGFg59sIYbxupx0EU4NtY33vJ1WRkYxmjEqqKEmIYvwW4cuSPg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>MicroRNA-363-3p promote the development of acute myeloid leukemia with RUNX1 mutation by targeting SPRYD4 and FNDC3B</title><source>PubMed (Medline)</source><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><source>IngentaConnect Journals</source><creator>Chen, Yimin ; Chen, Shuyi ; Lu, Jielun ; Yuan, Danyun ; He, Lang ; Qin, Pengfei ; Tan, Huo ; Xu, Lihua</creator><creatorcontrib>Chen, Yimin ; Chen, Shuyi ; Lu, Jielun ; Yuan, Danyun ; He, Lang ; Qin, Pengfei ; Tan, Huo ; Xu, Lihua</creatorcontrib><description>Runt-related transcription factor 1 (RUNX1) is one of the most frequently mutated genes in most of hematological malignancies, especially in acute myeloid leukemia. In the present study, we aimed to identify the key genes and microRNAs based on acute myeloid leukemia with RUNX1 mutation. The newly finding targeted genes and microRNA associated with RUNX1 may benefit to the clinical treatment in acute myeloid leukemia. The gene and miRNA expression data sets relating to RUNX1 mutation and wild-type adult acute myeloid leukemia (AML) patients were downloaded from The Cancer Genome Atlas database. Differentially expressed miRNAs and differentially expressed genes (DEGs) were identified by edgeR of R platform. Gene ontology and the Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed by Metascape and Gene set enrichment analysis. The protein-protein interaction network and miRNA-mRNA regulatory network were performed by Search Tool for the Retrieval of Interacting Genes database and Cytoscape software. A total of 27 differentially expressed miRNAs (25 upregulated and 2 downregulated) and 561 DEGs (429 upregulated and 132 downregulated) were identified. Five miRNAs (miR-151b, miR-151a-5p, let-7a-2-3p, miR-363-3p, miR-20b-5p) had prognostic significance in AML. The gene ontology analysis showed that upregulated DEGs suggested significant enrichment in MHC class II protein complex, extracellular structure organization, blood vessel development, cell morphogenesis involved in differentiation, embryonic morphogenesis, regulation of cell adhesion, and so on. Similarly, the downregulated DEGs were mainly enriched in secretory granule lumen, extracellular structure organization. In the gene set enrichment analysis of Kyoto Encyclopedia of Genes and Genomes pathways, the RUNX1 mutation was associated with adherent junction, WNT signaling pathway, JAK-STAT signaling pathway, pathways in cancer, cell adhesion molecules CAMs, MAPK signaling pathway. Eleven genes (PPBP, APP, CCR5, HLA-DRB1, GNAI1, APLNR, P2RY14, C3AR1, HTR1F, CXCL12, GNG11) were simultaneously identified by hub gene analysis and module analysis. MicroRNA-363-3p may promote the development of RUNX1 mutation AML, targeting SPRYD4 and FNDC3B. In addition, the RUNX1 mutation rates in patient were obviously correlated with age, white blood cell, FAB type, risk(cyto), and risk(molecular) (P &lt; .05). Our findings have indicated that multiple genes and microRNAs may play a crucial role in RUNX1 mutation AML. MicroRNA-363-3p may promote the development of RUNX1 mutation AML by targeting SPRYD4 and FNDC3B.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000025807</identifier><identifier>PMID: 33950983</identifier><language>eng</language><publisher>United States: Lippincott Williams &amp; Wilkins</publisher><subject>Carcinogenesis - genetics ; Clinical Trial/Experimental Study ; Computational Biology ; Core Binding Factor Alpha 2 Subunit - genetics ; Datasets as Topic ; Female ; Fibronectins - genetics ; Gene Expression Regulation, Leukemic ; Gene Regulatory Networks ; Humans ; Leukemia, Myeloid, Acute - genetics ; Leukemia, Myeloid, Acute - pathology ; Male ; MicroRNAs - metabolism ; Middle Aged ; Mutation ; Nuclear Proteins - genetics ; Protein Interaction Mapping ; Protein Interaction Maps - genetics</subject><ispartof>Medicine (Baltimore), 2021-05, Vol.100 (18), p.e25807-e25807</ispartof><rights>Lippincott Williams &amp; Wilkins</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.</rights><rights>Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. 2021</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4501-46aeeabdf432c1dd8c7eb8d29109869b34cb21808708dec5bda48c5eb137690a3</citedby><cites>FETCH-LOGICAL-c4501-46aeeabdf432c1dd8c7eb8d29109869b34cb21808708dec5bda48c5eb137690a3</cites><orcidid>0000-0002-3437-1286</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104143/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC8104143/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33950983$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Chen, Yimin</creatorcontrib><creatorcontrib>Chen, Shuyi</creatorcontrib><creatorcontrib>Lu, Jielun</creatorcontrib><creatorcontrib>Yuan, Danyun</creatorcontrib><creatorcontrib>He, Lang</creatorcontrib><creatorcontrib>Qin, Pengfei</creatorcontrib><creatorcontrib>Tan, Huo</creatorcontrib><creatorcontrib>Xu, Lihua</creatorcontrib><title>MicroRNA-363-3p promote the development of acute myeloid leukemia with RUNX1 mutation by targeting SPRYD4 and FNDC3B</title><title>Medicine (Baltimore)</title><addtitle>Medicine (Baltimore)</addtitle><description>Runt-related transcription factor 1 (RUNX1) is one of the most frequently mutated genes in most of hematological malignancies, especially in acute myeloid leukemia. In the present study, we aimed to identify the key genes and microRNAs based on acute myeloid leukemia with RUNX1 mutation. The newly finding targeted genes and microRNA associated with RUNX1 may benefit to the clinical treatment in acute myeloid leukemia. The gene and miRNA expression data sets relating to RUNX1 mutation and wild-type adult acute myeloid leukemia (AML) patients were downloaded from The Cancer Genome Atlas database. Differentially expressed miRNAs and differentially expressed genes (DEGs) were identified by edgeR of R platform. Gene ontology and the Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed by Metascape and Gene set enrichment analysis. The protein-protein interaction network and miRNA-mRNA regulatory network were performed by Search Tool for the Retrieval of Interacting Genes database and Cytoscape software. A total of 27 differentially expressed miRNAs (25 upregulated and 2 downregulated) and 561 DEGs (429 upregulated and 132 downregulated) were identified. Five miRNAs (miR-151b, miR-151a-5p, let-7a-2-3p, miR-363-3p, miR-20b-5p) had prognostic significance in AML. The gene ontology analysis showed that upregulated DEGs suggested significant enrichment in MHC class II protein complex, extracellular structure organization, blood vessel development, cell morphogenesis involved in differentiation, embryonic morphogenesis, regulation of cell adhesion, and so on. Similarly, the downregulated DEGs were mainly enriched in secretory granule lumen, extracellular structure organization. In the gene set enrichment analysis of Kyoto Encyclopedia of Genes and Genomes pathways, the RUNX1 mutation was associated with adherent junction, WNT signaling pathway, JAK-STAT signaling pathway, pathways in cancer, cell adhesion molecules CAMs, MAPK signaling pathway. Eleven genes (PPBP, APP, CCR5, HLA-DRB1, GNAI1, APLNR, P2RY14, C3AR1, HTR1F, CXCL12, GNG11) were simultaneously identified by hub gene analysis and module analysis. MicroRNA-363-3p may promote the development of RUNX1 mutation AML, targeting SPRYD4 and FNDC3B. In addition, the RUNX1 mutation rates in patient were obviously correlated with age, white blood cell, FAB type, risk(cyto), and risk(molecular) (P &lt; .05). Our findings have indicated that multiple genes and microRNAs may play a crucial role in RUNX1 mutation AML. MicroRNA-363-3p may promote the development of RUNX1 mutation AML by targeting SPRYD4 and FNDC3B.</description><subject>Carcinogenesis - genetics</subject><subject>Clinical Trial/Experimental Study</subject><subject>Computational Biology</subject><subject>Core Binding Factor Alpha 2 Subunit - genetics</subject><subject>Datasets as Topic</subject><subject>Female</subject><subject>Fibronectins - genetics</subject><subject>Gene Expression Regulation, Leukemic</subject><subject>Gene Regulatory Networks</subject><subject>Humans</subject><subject>Leukemia, Myeloid, Acute - genetics</subject><subject>Leukemia, Myeloid, Acute - pathology</subject><subject>Male</subject><subject>MicroRNAs - metabolism</subject><subject>Middle Aged</subject><subject>Mutation</subject><subject>Nuclear Proteins - genetics</subject><subject>Protein Interaction Mapping</subject><subject>Protein Interaction Maps - genetics</subject><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpdUdFu1DAQtBCIXgtfgIT8Ay52bMfOC1K5awGpd6CDSvBkOfHeJTSJI8fp6f6-bq-0lH1ZaWZnVrOL0DtGTxkt1Ifl4pQ-VSY1VS_QjEmeE1nk4iWa3aFEFUocoeNx_EMp4yoTr9ER54WkheYzFJdNFfx6dUZ4zgkf8BB85yPgWAN2cAOtHzroI_YbbKspEd0-YY3DLUzX0DUW75pY4_XV6hfD3RRtbHyPyz2ONmwhNv0W__i-_r0Q2PYOX6wWc_7pDXq1se0Ibx_6Cbq6OP85_0Iuv33-Oj-7JJWQlBGRWwBbuo3gWcWc05WCUrusSPF1XpRcVGXGNNWKageVLJ0VupJQpph5QS0_QR8PvsNUduCqlCPY1gyh6WzYG28b85zpm9ps_Y3RjAomeDLgB4N0o3EMsHnUMmrunmCWC_P_E5Lq_b9rHzV_r54GxGFg59sIYbxupx0EU4NtY33vJ1WRkYxmjEqqKEmIYvwW4cuSPg</recordid><startdate>20210507</startdate><enddate>20210507</enddate><creator>Chen, Yimin</creator><creator>Chen, Shuyi</creator><creator>Lu, Jielun</creator><creator>Yuan, Danyun</creator><creator>He, Lang</creator><creator>Qin, Pengfei</creator><creator>Tan, Huo</creator><creator>Xu, Lihua</creator><general>Lippincott Williams &amp; Wilkins</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3437-1286</orcidid></search><sort><creationdate>20210507</creationdate><title>MicroRNA-363-3p promote the development of acute myeloid leukemia with RUNX1 mutation by targeting SPRYD4 and FNDC3B</title><author>Chen, Yimin ; Chen, Shuyi ; Lu, Jielun ; Yuan, Danyun ; He, Lang ; Qin, Pengfei ; Tan, Huo ; Xu, Lihua</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4501-46aeeabdf432c1dd8c7eb8d29109869b34cb21808708dec5bda48c5eb137690a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Carcinogenesis - genetics</topic><topic>Clinical Trial/Experimental Study</topic><topic>Computational Biology</topic><topic>Core Binding Factor Alpha 2 Subunit - genetics</topic><topic>Datasets as Topic</topic><topic>Female</topic><topic>Fibronectins - genetics</topic><topic>Gene Expression Regulation, Leukemic</topic><topic>Gene Regulatory Networks</topic><topic>Humans</topic><topic>Leukemia, Myeloid, Acute - genetics</topic><topic>Leukemia, Myeloid, Acute - pathology</topic><topic>Male</topic><topic>MicroRNAs - metabolism</topic><topic>Middle Aged</topic><topic>Mutation</topic><topic>Nuclear Proteins - genetics</topic><topic>Protein Interaction Mapping</topic><topic>Protein Interaction Maps - genetics</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Chen, Yimin</creatorcontrib><creatorcontrib>Chen, Shuyi</creatorcontrib><creatorcontrib>Lu, Jielun</creatorcontrib><creatorcontrib>Yuan, Danyun</creatorcontrib><creatorcontrib>He, Lang</creatorcontrib><creatorcontrib>Qin, Pengfei</creatorcontrib><creatorcontrib>Tan, Huo</creatorcontrib><creatorcontrib>Xu, Lihua</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Chen, Yimin</au><au>Chen, Shuyi</au><au>Lu, Jielun</au><au>Yuan, Danyun</au><au>He, Lang</au><au>Qin, Pengfei</au><au>Tan, Huo</au><au>Xu, Lihua</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MicroRNA-363-3p promote the development of acute myeloid leukemia with RUNX1 mutation by targeting SPRYD4 and FNDC3B</atitle><jtitle>Medicine (Baltimore)</jtitle><addtitle>Medicine (Baltimore)</addtitle><date>2021-05-07</date><risdate>2021</risdate><volume>100</volume><issue>18</issue><spage>e25807</spage><epage>e25807</epage><pages>e25807-e25807</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Runt-related transcription factor 1 (RUNX1) is one of the most frequently mutated genes in most of hematological malignancies, especially in acute myeloid leukemia. In the present study, we aimed to identify the key genes and microRNAs based on acute myeloid leukemia with RUNX1 mutation. The newly finding targeted genes and microRNA associated with RUNX1 may benefit to the clinical treatment in acute myeloid leukemia. The gene and miRNA expression data sets relating to RUNX1 mutation and wild-type adult acute myeloid leukemia (AML) patients were downloaded from The Cancer Genome Atlas database. Differentially expressed miRNAs and differentially expressed genes (DEGs) were identified by edgeR of R platform. Gene ontology and the Kyoto Encyclopedia of Genes and Genomes enrichment analyses were performed by Metascape and Gene set enrichment analysis. The protein-protein interaction network and miRNA-mRNA regulatory network were performed by Search Tool for the Retrieval of Interacting Genes database and Cytoscape software. A total of 27 differentially expressed miRNAs (25 upregulated and 2 downregulated) and 561 DEGs (429 upregulated and 132 downregulated) were identified. Five miRNAs (miR-151b, miR-151a-5p, let-7a-2-3p, miR-363-3p, miR-20b-5p) had prognostic significance in AML. The gene ontology analysis showed that upregulated DEGs suggested significant enrichment in MHC class II protein complex, extracellular structure organization, blood vessel development, cell morphogenesis involved in differentiation, embryonic morphogenesis, regulation of cell adhesion, and so on. Similarly, the downregulated DEGs were mainly enriched in secretory granule lumen, extracellular structure organization. In the gene set enrichment analysis of Kyoto Encyclopedia of Genes and Genomes pathways, the RUNX1 mutation was associated with adherent junction, WNT signaling pathway, JAK-STAT signaling pathway, pathways in cancer, cell adhesion molecules CAMs, MAPK signaling pathway. Eleven genes (PPBP, APP, CCR5, HLA-DRB1, GNAI1, APLNR, P2RY14, C3AR1, HTR1F, CXCL12, GNG11) were simultaneously identified by hub gene analysis and module analysis. MicroRNA-363-3p may promote the development of RUNX1 mutation AML, targeting SPRYD4 and FNDC3B. In addition, the RUNX1 mutation rates in patient were obviously correlated with age, white blood cell, FAB type, risk(cyto), and risk(molecular) (P &lt; .05). Our findings have indicated that multiple genes and microRNAs may play a crucial role in RUNX1 mutation AML. MicroRNA-363-3p may promote the development of RUNX1 mutation AML by targeting SPRYD4 and FNDC3B.</abstract><cop>United States</cop><pub>Lippincott Williams &amp; Wilkins</pub><pmid>33950983</pmid><doi>10.1097/MD.0000000000025807</doi><orcidid>https://orcid.org/0000-0002-3437-1286</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2021-05, Vol.100 (18), p.e25807-e25807
issn 0025-7974
1536-5964
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_8104143
source PubMed (Medline); HEAL-Link subscriptions: Lippincott Williams & Wilkins; IngentaConnect Journals
subjects Carcinogenesis - genetics
Clinical Trial/Experimental Study
Computational Biology
Core Binding Factor Alpha 2 Subunit - genetics
Datasets as Topic
Female
Fibronectins - genetics
Gene Expression Regulation, Leukemic
Gene Regulatory Networks
Humans
Leukemia, Myeloid, Acute - genetics
Leukemia, Myeloid, Acute - pathology
Male
MicroRNAs - metabolism
Middle Aged
Mutation
Nuclear Proteins - genetics
Protein Interaction Mapping
Protein Interaction Maps - genetics
title MicroRNA-363-3p promote the development of acute myeloid leukemia with RUNX1 mutation by targeting SPRYD4 and FNDC3B
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-27T08%3A38%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MicroRNA-363-3p%20promote%20the%20development%20of%20acute%20myeloid%20leukemia%20with%20RUNX1%20mutation%20by%20targeting%20SPRYD4%20and%20FNDC3B&rft.jtitle=Medicine%20(Baltimore)&rft.au=Chen,%20Yimin&rft.date=2021-05-07&rft.volume=100&rft.issue=18&rft.spage=e25807&rft.epage=e25807&rft.pages=e25807-e25807&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000025807&rft_dat=%3Cpubmed_cross%3E33950983%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c4501-46aeeabdf432c1dd8c7eb8d29109869b34cb21808708dec5bda48c5eb137690a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/33950983&rfr_iscdi=true